South KoreaHealthcare and life sciences2024 – ongoingChaperone Therapeutics
AIDEN, an in-house AI platform for small-molecule drug discovery
Chaperone Therapeutics said its AIDEN platform predicts drug efficacy and toxicity with up to 98% accuracy
Problem
Finding a small-molecule drug candidate normally takes long rounds of testing to judge efficacy and toxicity.
Approach
Chaperone built AIDEN in-house to predict the efficacy and toxicity of small molecules. The company said it used the platform to identify a compound with more than 100 times the efficacy of a competing substance within six months. The drugs it helped develop were still in clinical trials.
Results
Takeaway
The accuracy and efficacy figures came from the company's chief executive in an interview. None of the compounds had reached approval.
Categories
- Size
- Small business
- Industry
- Healthcare and life sciences
- Business function
- IT and R&D
- Innovation type
- Process innovation
- AI technology
- Predictive analytics and ML
- Adoption
- Built in-house
- Evidence
- Company's own claim
Sources
Source summaries
Interview-based feature on Chaperone. It says the in-house AIDEN platform reached prediction accuracy of up to 98% and helped find a compound with over 100 times the efficacy of a competitor within six months. The company's drug candidates were still in clinical trials.
Full details are in the original sources.